# RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

> **NCT02489903** · PHASE2 · COMPLETED · sponsor: **EpicentRx, Inc.** · enrollment: 139 (actual)

## Conditions studied

- Small Cell Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Neuroendocrine Tumors
- Ovarian Epithelial Cancer

## Interventions

- **DRUG:** RRx-001
- **DRUG:** Cisplatin
- **DRUG:** Etoposide
- **DRUG:** Carboplatin
- **DRUG:** Irinotecan
- **DRUG:** Vinorelbine
- **DRUG:** Doxil
- **DRUG:** Gemcitabine
- **DRUG:** Taxane
- **DRUG:** Paclitaxel
- **DRUG:** Nab-Paclitaxel
- **DRUG:** Pemetrexed

## Key facts

- **NCT ID:** NCT02489903
- **Lead sponsor:** EpicentRx, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-06
- **Primary completion:** 2021-12-06
- **Final completion:** 2021-12-06
- **Target enrollment:** 139 (ACTUAL)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02489903

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02489903, "RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT02489903. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*